It found that a multicenter study of 16 patients with stage IV breast cancer described vitiligo-like lesions observed during treatment with CDK4/6 inhibitors (14 out of 16 treated with ribociclib and 2 out of 16 with palbociclib), identifying it as a rare but well-documented manifestation [10,11,12]. The gene discussed is CDK4; the disease is vitiligo.